Physician profile
Bret K Sohn
NPI 1982994836
$447,346.93
in general payments reported to CMS, 2019-2025
18 companies · $242K in 2025
The $242K reported for 2025 was more than what 99% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $463 · 2021: $2,768 · 2022: $7,847 · 2023: $49K · 2024: $145K · 2025: $242K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $333K · Consulting Fee: $47K · Travel and Lodging: $43K · Food and Beverage: $13K · Education: $344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $332,606.00 |
| Consulting Fee | $47,447.50 |
| Travel and Lodging | $42,684.96 |
| Food and Beverage | $12,942.14 |
| Education | $343.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $200,571.56 | 2020-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $183,554.47 | 2021-2025 | Tremfya, Simponi Aria |
| Amgen INC. | $49,345.12 | 2019-2025 | Uplizna, Krystexxa, Tavneos |
| Abbvie INC. | $9,643.49 | 2019-2025 | |
| Ucb Sa | $1,380.00 | 2023-2025 | Bimzelx |
| Janssen Scientific Affairs, LLC | $1,018.27 | 2023-2024 | Tremfya, Simponi Aria, Stelara |
| Lilly USA, LLC | $468.41 | 2021-2025 | |
| Pfizer INC. | $429.63 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $341.92 | 2021-2025 | |
| Glaxosmithkline, LLC. | $217.13 | 2021-2025 | Benlysta |
| Aurinia Pharma U.S., INC. | $103.30 | 2021-2022 | |
| Cardinal Health 110 LLC | $100.00 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $62.99 | 2021-2022 | |
| Amarin Pharma, INC. | $37.64 | 2021 | |
| Invivyd INC | $27.41 | 2025 | Pemgarda |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $17.98 | 2019 | |
| Horizon Therapeutics Plc | $15.11 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bret Sohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.